CBD, for millions of people, has become a go-to alternative medicine. Around the globe, more people have accepted the previously contested notion that cannabis effectively treats myriad ailments and offers relief for symptoms related to a host of other medical issues. But as interest in CBD grows, so does the demand for other cannabinoids. And for manufacturers and marketers of CBD products, it may be time to expand beyond CBD if you have not yet considered it.
Enter CBC (cannabichromene) and CBN (cannabinol), two powerful and effective cannabinoids that have entered the retail market. Hemp professionals already know about CBC and CBN, whether it’s a basic knowledge of their properties or years of experience processing them for retailers. But despite the insular knowledge of CBC and CBN, there’s limited information available to interested buyers in the CBD market. There’s an opportunity to educate consumers about the purported properties of both cannabinoids, and offering those resources could position product manufacturers and retailers in the industry as credible and forward-thinking leaders in our industry. Here’s what your consumers need to know, as they buy the products that fuel the industry’s supply chain:
Cannabichromene is one of the estimated 100+ cannabinoids found in C. sativa, discovered in 1966. Its properties have been well-researched by chemists and scientists who have suggested that CBC is effective at reducing pain and modulating immune system response. The compound has also been researched and studied as a treatment for other ailments like Irritable Bowel Syndrome, acne, glaucoma, neurobehavioral disorders, and inflammation. Researchers have also suggested that CBC can be helpful with pain modulation when combined with CBD, according to continued research about the way CBC interacts with the body’s physiological response to pain.
Cannabinol has become a leading contender in alternative treatments for sleep disorders like insomnia. Similar to CBD, CBN is a non-intoxicating cannabinoid found in C. sativa, though it is hard to access as it usually comprises less than 1% of cannabis plants. Research suggests that cannabinol’s interaction with the human endocannabinoid system (the biological system that regulates bodily functions including sleep) helps to enhance the body’s state of homeostasis, which ECS already controls. CBN responds to CB2, a primary cannabinoid receptor in the endocannabinoid system, which instigates positive therapeutic responses for sleep, pain, and mood.
CBC and CBN are somewhat uncharted territory in the retail CBD industry, particularly for consumers who are just learning about CBD and its myriad benefits. Consumers should know that CBN and CBC are equally as effective and promising as CBD and that their properties suggest more potential, targeted health benefits. These are opportunities for retailers to consider, especially in an environment where people are looking to be healthier and enhance the quality of their lives. Looking beyond CBD, there are massive opportunities for change, as well as opportunities for partnership and leadership.
The information provided herein may be subject to change and should be independently verified. These statements have not been evaluated by the Food and Drug Association and are not intended to diagnose, treat, cure, or prevent any disease.